digi·access - Improve accessibility
Optimize the website for better readability and user experience.
F2 to open
The page is reloaded when used
English
Deutsch
English
Español
Français
Italiano
Nederlands
Polski
Čeština
Türkiye
Dansk
Svenska
Suomi
Português
Norsk
Slovenčina
Magyar
Tiếng Việt
Adjustments for accessibility
Choose your settings
Visually impaired people Support for people with poor eyesight
Off
On
Reading texts aloud Assistance for users who have problems reading online texts
Off
On
Cognitive Restrictions Provides assistance to read and recognise important elements
Off
On
Epileptics Animations are deactivated and dangerous colour combinations reduced
Off
On
ADHD settings Distractions are reduced and a clear focus is set
Off
On
Blind People The screen reader can recognise contents of the web page
Off
On
Motor impaired people The website can be navigated via keyboard
Off
On
Reset all settings Your adjustments for accessibility are set back to the standard settings
Reset
Individual adjustments
Font size
Reset
Line spacing
Reset
Content size
Reset
Word spacing
Reset
Black / white Hide images Highlighting Mouse Simple font
Stop animations Mute sound Reading Mask Magnifier
Extended adjustments
Character spacing
Reset
Highlight link Large pointer
Virtual keyboard Saturation Contrast Video
Background colour
Reset
Text colour
Reset
Link colour
Reset
Title colour
Reset
Close
Reset
Hide widget
Barrierefreie Webseite mit digi·access GmbH, Version 3.47.12 Copyright © 2026
Hide digi·smartPlugin?
Once hidden, it will only be available again by deleting your browser data. Do you want to continue?
Cancel Confirm
Redirect
You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.
Let's go Cancel
Internet Explorer is not supported
You are using an outdated browser. If you would like to use our website, please use Chrome, Firefox, Safari or other browser
Accept
Share Disclaimer
By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement.
OK Cancel
{"analytics":"targeting"}

Disclaimer
Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.
Accept
Skip to main content
Select your Market
-
Africa
-
Asia
-
Europe
-
Latin America
-
North America
-
Oceania
{{ cartLength }}
DE Change language to German
EN
You are currently browsing content in English
Our share price
€150.9
0.40%
0 matching results. Select 'Show All Results' link to see additional results
Discover with us

FY 2025 Online Report

Chat with our AI assistant

Build what's next with us.
0 matching results. Select 'Show All Results' link to see additional results
Discover with us

FY 2025 Online Report

Chat with our AI assistant

Build what's next with us.
- Company
-
Expertise
-
Research
-
News & Media
-
Investors
Global
DE Change language to German EN You are currently browsing content in English
Merck Opens €300 Million Asia-Pacific Bioprocessing Center in Daejeon, South Korea
Merck opened a €300 million Daejeon center, expanding regional capacity and access to critical bioprocessing materials.
Share Icons revealed to the left
29 Oct 2026 | Darmstadt, Germany
-
Merck’s largest life science investment in Asia-Pacific to date expands regional manufacturing capacity
-
Integrated digital systems support automated data capture and end-to-end batch traceability
-
Advances Merck’s in-region-for-region strategy, bringing critical products closer to customers across Asia-Pacific
-
State-of-the-art facility designed to eliminate on-site fossil-fuel use and improve energy and water efficiency
Merck, a leading science and technology company, today opened its new Asia-Pacific Bioprocessing Production Center in Daejeon, South Korea. The center represents an investment of more than €300 million, the company’s largest Life Science investment in Asia-Pacific to date.
The 44,500-square-meter site expands the Merck’s regional manufacturing capacity for critical materials and solutions used in the development and production of biologic medicines. It gives biopharmaceutical manufacturers across Asia-Pacific closer access to the materials and solutions needed to develop and produce biologic medicines.
"Reliable access to critical materials is essential at every stage of biologics manufacturing,” said Jean-Charles Wirth, Member of the Executive Board of Merck, and CEO Life Science. “Daejeon brings advanced production closer to biopharma manufacturers across Asia-Pacific, giving them greater supply confidence, as they move from development to commercial scale. The center adds the regional capacity customers need and delivers the quality and consistency they expect from Merck.”
From Daejeon, Merck will supply bioprocessing products used from early process development through commercial-scale manufacturing. These include cell culture media in dry powder and liquid formats, including pre-GMP small-scale custom products through imMEDIAte ADVANTAGE®, process liquids and ready-to-use cleaning-in-place solutions; and single-use sterile sampling solutions based on the NovaSeptum® Sterile Sampling System. Together, they help customers accelerate development, scale production, maintain controlled manufacturing environments and reduce contamination risk. Cell culture media and process liquids will use animal-component-free raw materials and be manufactured to consistent global quality standards.
“The completion of Merck’s Asia-Pacific Bioprocessing Production Center, a world-leading bioscience company, marks a historic turning point in Daejeon’s rise as a global bio hub—not just for Korea, but for the world." said Tae-Jeong Heo, Mayor of Daejeon. “We will provide our full support to ensure that Merck’s foundational technologies at the Daedeok Innopolis and the capabilities of the local community can be brought together seamlessly. We will focus the city’s resources on building a world-class global bio ecosystem through close collaboration among industry, academia, research institutions, and hospitals.”
The center’s integrated digital ecosystem is designed to support automated data capture and end-to-end batch traceability, increasing process transparency and supporting quality management and regulatory compliance.
The facility is designed to eliminate the use of fossil fuels on-site while increasing energy and water efficiency through the use of solar power, a heat-pump system, energy recovery in air handling units, and rainwater reuse.
The Daejeon center is a key part of Merck’s in-region-for-region strategy. It builds on recent investments across the company’s global network, including BioReliance® drug product testing in Darmstadt, Germany, and filtration manufacturing in Blarney, Ireland. Across this network, Merck is bringing critical products and services closer to customers while applying consistent global quality standards.
Downloads
- Merck-Opens-Asia-Pacific-Bioprocessing-Production-Center-in-Daejeon-EN.pdf
- daejeon-opening-merck.jpg